Skip to main content
SpringerLink
Log in

Prävention rezidivierender Thromboembolien

WARFASA (Aspirin for the Prevention of Recurrent Venous Thromboembolism – the Warfarin and Aspirin Study)

Prevention of recurrent thromboembolisms

WARFASA (Aspirin for the Prevention of Recurrent Venous Thromboembolism – the Warfarin and Aspirin Study)

  • Klinische Studien
  • Published:
Der Internist Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Becattini C, Agnelli G, Schenone A et al (2012) Aspirin for preventing the recurrence of venous thromboembolism. N Engl J Med 366:1959–1967

    Google Scholar 

  2. Brighton TA, Eikelboom JW, Mann K et al (2012) Low-dose aspirin for preventing recurrent venous thromboembolism. N Engl J Med 367:1979–1987

    Google Scholar 

  3. Brill A, Fuchs TA, Savchenko AS et al (2012) Neutrophil extracellular traps promote deep vein thrombosis in mice. J Thromb Haemost 10:136–144

    Google Scholar 

  4. Kearon C, Akl EA, Comerota AJ et al (2012) Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141(2 Suppl):e419S–e494S

    Article  PubMed  CAS  Google Scholar 

  5. Prandoni P, Noventa F, Ghirarduzzi A et al (2007) The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients. Haematologica 92:199–205

    Article  PubMed  Google Scholar 

  6. Bruhl ML von, Stark K, Steinhart A et al (2012) Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice in vivo. J Exp Med 209:819–835

    Google Scholar 

Download references

Einhaltung ethischer Richtlinien

Interessenkonflikt. D. Duerschmied, S. Nitschmann und C. Bode geben an, dass kein Interessenkonflikt besteht. C. Bode: Forschungmittel von REGADO, Merck, Sanofi-Aventis, Bayer, GlaxoSmithKline, Astellas; Vortragshonorare von Bristol-Myers Squibb/Pfizer, Daiichi-Sankyo, Boehringer Ingelheim, Sanofi-Aventis, Novartis, AstraZeneca, Lilly; Beraterhonorare von Merck, Bayer Healthcare, Boehringer Ingelheim, Sanofi-Aventis. Dieser Beitrag beinhaltet keine Studien an Menschen oder Tieren.

Author information

Authors and Affiliations

  1. Kardiologie und Angiologie I, Universitäts-Herzzentrum Freiburg – Bad Krozingen, Hugstetter Str. 55, 79106, Freiburg, Deutschland

    D. Duerschmied & C. Bode

  2. Werl-Westönnen, Deutschland

    S. Nitschmann

Authors
  1. D. Duerschmied
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S. Nitschmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. C. Bode
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to D. Duerschmied.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Duerschmied, D., Nitschmann, S. & Bode, C. Prävention rezidivierender Thromboembolien. Internist 54, 1393–1396 (2013). https://doi.org/10.1007/s00108-013-3377-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00108-013-3377-6

Search

Navigation